Waking up dormant HIV

Mar 16, 2009

HAART (highly active anti-retroviral therapy) has emerged as an extremely effective HIV treatment that keeps virus levels almost undetectable; however, HAART can never truly eradicate the virus as some HIV always remains dormant in cells. But, a chemical called suberoylanilide hydroxamic acid (SAHA), recently approved as a leukemia drug, has now been shown to 'turn on' latent HIV, making it an attractive candidate to weed out the hidden virus that HAART misses.

Matija Peterlin at UCSF and colleagues had previously identified another chemical called HMBA that could activate latent , but the risk of several toxic side effects made HMBA clinically non-viable. However, the chemically similar SAHA had received FDA approval, making it a potentially safer alternate.

So, the researchers examined whether SAHA had any effect on HIV latency. They found that SAHA could indeed stimulate to begin replicating, which exposes the infected cell to HAART drugs. SAHA could activate HIV in both laboratory as well as from blood samples taken from HIV patients on antiretroviral therapy. Importantly, this successful activation was achieved using clinical doses of SAHA, suggesting toxicity will not be a problem.

More information: This study appeared in the March 13 issue of , "Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells" by Xavier Contreras, Marc Schwenker, Chin-Shih Chen, Joseph M. McCune, Steven G. Deeks, Jeffrey Martin, and B. Matija Peterlin
Article link: www.jbc.org/cgi/content/full/284/11/6782

Source: American Society for Biochemistry and Molecular Biology

Explore further: Forced mutations doom HIV: New study reveals how a potential HIV drug exacts its toll on viral populations

add to favorites email to friend print save as pdf

Related Stories

Human testis harbors HIV-1 in resident immune cells

Nov 27, 2006

Researchers have demonstrated HIV replication within resident immune cells of the testis, providing an explanation for the persistence of virus in semen even after effective highly active antiretroviral therapy. The related ...

Researchers disprove long-standing belief about HIV treatment

Jul 25, 2008

Researchers at Wake Forest University Baptist Medical Center have disproved a long-standing clinical belief that the hepatitis C virus slows or stunts the immune system's ability to restore itself after HIV patients are treated ...

FDA approves antiretroviral drug

Aug 07, 2007

The U.S. Food and Drug Administration has approved the antiretroviral drug maraviroc for use in adult human immunodeficiency virus patients.

HIV measurement is questioned

Sep 27, 2006

Preliminary U.S. research indicates the HIV RNA level in untreated HIV-infected patients has little value in predicting the rate of CD4 cell count decrease.

Researchers' new goal: Drug-free remission for HIV infection

Mar 05, 2009

A group including leading academic and industry scientists has issued a challenge to researchers in the field of HIV/AIDS: find a way to effectively purge latent HIV infection and eliminate the need for chronic, suppressive ...

Recommended for you

Clinical trial of herpes vaccine now enrolling patients

Jul 28, 2014

Creating a successful vaccine against two members of the family, the sexually transmitted herpes simplex virus 1 (HSV-1) and 2 (HSV-2), has proven to be challenging. A clinical trial being conducted by a ...

Lift U.S. ban on blood donations by gay men, experts say

Jul 25, 2014

(HealthDay)—The United States should repeal a 30-year policy that bans blood donations from gay and bisexual men, according to a team of medical and legal experts writing this week in the Journal of th ...

How we got ahead in HIV control

Jul 25, 2014

When AIDS first emerged in the early 1980s, HIV infection was a death sentence. But a global effort has ensured this is no longer the case for a growing number of people.

User comments : 0